Levonorgestrel, Pharmacokinetics, Efficacy and Safety 71[111] Radesic B, Sharma A. Levonorgestrel releasing intrauterine system for
treating menstrual disorders: a patient satisfaction questionnaire. Aust N
Z J Obstet Gynaecol. 2004; 44:247–251.
[112] Lethaby AE, Cooke I, Rees M. Progesterone/progestogen
releasingintrauterine systems versus either placebo or any other
medication for heavy menstrual bleeding. Cochrane Database Syst Rev
2000;2:CD002126.
[113] French R, Van Vliet H, Cowan F, Mansour D, Morris S, Hughes D et al.
Hormonally impregnated intrauterine systems (IUSs) versus other forms
of reversible contra-ceptives as effective methods of preventing
pregnancy. Cochrane Database Syst Rev 2004;3:CD001776.
[114] National Collaborating Centre for Women's and Children's Health.
Long-acting reversible contraception the effective and appropriate use of
long-acting reversible contraception. London, UK: RCOG Press
2005[Booklet].
[115] Ornstein RM, Fisher MM. Hormonal contraception in adolescents:
special considerations. Paediatr Drugs. 2006;8: 25–45.
[116] Qin LH, Goldberg JM, Hao G. A 4-year follow-up study of women with
Norplant-2 contraceptive implants. Contraception. 2001; 64: 301–303.
[117] Booranabunyat S, Taneepanichskul S. Implanon use in Thai women
above the age of 35 years. Contraception. 2004; 69: 489– 491
[118] Paterson H, Clifton J, Miller D, Ashton J, Harrison-Woolrych M. Hair
loss with use of the levonorgestrel intrauterine device. Contraception.
2007;76:306-309.
[119] Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED Ovarian
function during use of a levonorgestrel-releasing IUD Contraception.
1990; 42: 51–66.
[120] Mercke Y, Sheng T, Khan T, Lippmann S. Hair loss in
psychopharmacology. Ann Clin Psychiatry. 2000; 12: 35-42.
[121] Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids.
2000;65: 651-658.
[122] Endrikat J, Klipping C, Cronin M. An open label, comparative study of
the effects of a dose-reduced oral contraceptive containing 20μg ethinyl
estradiol and 100 μg levonorgestrel on hemostatic, lipids, and
carbohydrate metabolism variables. Contraception. 2002;65:215-221.
[123] Skouby SO, Endrikat J, Dusterberg B. A 1-year randomized study to
evaluate the effects of a dose reduction in oral contraceptives on lipids
and carbohydrate metabolism: 20μg ethinyl estradiol combined with
100μg levonorgestrel. Contraception. 2005;71:111-117.